Rosiglitazone (155141-29-0) is a highly selective (KD = 40 nM)2 and potent (IC50 = 9 nM, human adipocytes)3 agonist for the peroxisome proliferator-activated receptor gamma (PPARγ). Rosiglitazone is a clinically approved antidiabetic agent that improves glycemic control by improving insulin sensitivity.
1) Cantello et al. (1994), [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents; J. Med. Chem., 37 3977
2) Lehmann et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma); J. Biol. Chem., 270 12953
3) Young et al. (1998), Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma; J.Pharmacol. Exp. Ther., 284 751